Andrew Gilder

Andrew Gilder is a Senior Process Engineer at Shoreline Biosciences, Inc. since May 2023, with prior experience as a Scientist at Fate Therapeutics Inc. where process development for iPSC derived cancer immunotherapies was a focus. During tenure at Fate Therapeutics, Andrew led R&D efforts supporting IND enabling activities for multiple CAR-NK drug product candidates. At Hologic, Andrew contributed to assay development in molecular diagnostics. An academic background includes roles as Assistant Project Scientist and Postdoctoral Scholar at the University of California, San Diego School of Medicine, studying cell signaling related to cancer and inflammation under Steven Gonias. Andrew holds a Ph.D. in Biochemistry from the University of Mississippi Medical Center and a Bachelor of Science in Economics and Biology from Millsaps College.